Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RELMADA THERAPEUTICS, INC. Director's Dealing 2017

Oct 6, 2017

34465_dirs_2017-10-06_7290c3c7-f1d7-4117-b18f-18bff672ff45.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2017-10-04

Reporting Person: Kelly Paul Edward (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-10-04 Convertible Note $0.75 P 200000 Acquired 2019-10-04 Common stock (200000) Direct
2017-10-04 Warrant $1.50 P 100000 Acquired 2024-10-04 Common stock (100000) Direct